AbbVie Is Maintained at Neutral by B of A Securities
AbbVie Analyst Ratings
BofA Securities Initiates AbbVie(ABBV.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), AbbVie (ABBV) and Elevance Health (ELV)
AbbVie Is Maintained at Outperform by BMO Capital
BMO Capital Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $220
AbbVie Price Target Announced at $203.00/Share by Bernstein
AbbVie Analyst Ratings
AbbVie Initiated With a Market Perform at Bernstein
Wells Fargo Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $205
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Ionis Pharmaceuticals (IONS) and Amicus (FOLD)
Morgan Stanley Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $218
Truist Financial Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $215
UBS Downgrades AbbVie(ABBV.US) to Hold Rating, Raises Target Price to $195
TD Cowen Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $225
AbbVie Is Maintained at Buy by TD Cowen
AbbVie Analyst Ratings
Barclays Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $212
AbbVie (ABBV) Gets a Buy From Barclays
Barclays Adjusts Price Target on AbbVie to $212 From $200, Maintains Overweight Rating